Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Five patients with chronic hepatitis B were treated with 8-day courses of leukocyte (alpha) interferon (5 X 10(6) U/day) and with 8-day courses of recombinant fibroblast (betaser) interferon at dosages of 5 X 10(6), 35 X 10(6), and 105 X 10(6) U/day. Inhibition of hepatitis B virus replication as ev...

詳細記述

書誌詳細

出版年:	Antimicrob Agents Chemother
主要な著者:	Eisenberg, M, Rosno, S, Garcia, G, Konrad, M W, Gregory, P B, Robinson, W S, Merigan, T C
フォーマット:	Artigo
言語:	Inglês
出版事項:	American Society for Microbiology (ASM) 1986
主題:	Research Article
オンライン･アクセス:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180376/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3524420/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.29.1.122
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!